Anti-Human LAG-3 Recombinant Nanobody (SAA2195) (HB613013)

Name: Anti-Human LAG-3 Recombinant Nanobody (SAA2195)
Brand: abinScience
SKU: HB613013
Price: 126 USD
Availability: InStock

Даташит Поделиться продуктом Копировать информацию

Цена(USD):

Спецификация:

20ug
50ug
100ug
1mg

Количество:

Свяжитесь с нами

Обзор
Изображения
Ссылки
Даташит
SDS

Обзор

Каталожный номер

HB613013

Описание

Anti-Human LAG3 Nanobody (SAA2195) [SAA2195] (HB613013) is a alpaca monoclonal antibody detecting LAG3 in ELISA. Suitable for Human.

Реактивность видов

Human

Применения

ELISA

Хозяинский вид

Alpaca

Клоональность

Monoclonal

Изотип

VHH-8His-Cys-tag

ID клона

SAA2195

Цель

CD223, FDC, LAG-3, LAG3, Lymphocyte activation gene 3 protein, Secreted lymphocyte activation gene 3 protein, sLAG-3

Уровень эндотоксинов

< 10 EU/mg

Чистота

>95% as determined by SDS-PAGE.

Очистка

Protein A/G purified from cell culture supernatant.

Номер доступа

P18627

Форма

Liquid

Буфер хранения

0.01M PBS pH 7.4.

Пожалуйста, обратитесь к конкретной информации о буфере в печатной версии даташита или в индивидуальном сертификате качества (COA) для партии.

Информация об использовании продукта

Применение	Разбавление
ELISA	1:2000-1:20000

Устойчивость и хранение

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Фон

Lymphocyte activation gene 3 protein (CD223/LAG3) is a ~57 kDa protein. Inhibitory receptor on antigen activated T-cells. Delivers inhibitory signals upon binding to ligands, such as MHC class II, its main ligand present at the surface of antigen-presenting cells (APCs), and FGL1, which is secreted by hepatocytes and certain types of tumor cells. Ligand-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation. Mechanistically, ligand-binding promotes (1) ubiquitination of the KIEELE motif, unleashing the RRFSALE motif from the membrane and (2) leading to the formation of condensates with the TCR component CD3E, thereby disrupting the association between CD3E and LCK and preventing TCR activation. May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1. CD223 is the therapeutic target of relatlimab (Opdualag).

1. Camisaschi, C. et al. (2010) Journal of immunology (Baltimore, Md. : 1950) 184, 6545-51. PMID: 20421648

2. Ming, Q. et al. (2022) Nature immunology 23, 1031-1041. PMID: 35761082

3. Huard, B. et al. (1994) European journal of immunology 24, 3216-21. PMID: 7805750

4. Huard, B. et al. (1996) European journal of immunology 26, 1180-6. PMID: 8647185

5. Wang, J. et al. (2019) Cell 176, 334-347.e12. PMID: 30580966

6. MacLachlan, BJ. et al. (2021) European journal of immunology 51, 331-341. PMID: 32920841

7. Petersen, J. et al. (2024) Science immunology 9, eads5122. PMID: 39671469

8. Huard, B. et al. (1995) European journal of immunology 25, 2718-21. PMID: 7589152

10. Jiang, Y. et al. (2025) Cell 188, 2354-2371.e18. PMID: 40101708

Примечание

For research use only.

Изображения

SDS-PAGE

SDS-PAGE for Anti-Human LAG3 Nanobody (SAA2195)

Ссылки

Даташит

Anti-Human LAG-3 Recombinant Nanobody (SAA2195).pdf

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

Рекомбинантные Белки

Антитела

Наборы для анализа